DOI:
10.1055/s-00000036
Laryngo-Rhino-Otologie
LinksClose Window
References
Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby RF, Harrington KJ.
KEYNOTE-040 investigators. Pembrolizumab versus methotrexate, docetaxel, or
cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma
(KEYNOTE-040): a randomised, open-label, phase 3 study.
Lancet 2019;
393: 156-167
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.